Quantitative analysis of expression levels of bax, bcl-2, and survivin in cancer cells during cisplatin treatment

  • Authors:
    • Masahide Ikeguchi
    • Seiichi Nakamura
    • Nobuaki Kaibara
  • View Affiliations

  • Published online on: September 1, 2002     https://doi.org/10.3892/or.9.5.1121
  • Pages: 1121-1126
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Cisplatin (CDDP) exerts significant activity against a wide variety of human malignancies. However, sensitivity to CDDP differs among cancer cells. CDDP induces apoptosis in cancer cells. In the present study, to evaluate good markers of chemo-sensitivity or chemo-resistance of cancer cells, the correlation between occurrence of apoptosis and the changes in expression levels of messenger RNA (mRNA) of three genes (bax, bcl-2, and survivin) in cancer cell lines during CDDP treatment were investigated. Cells (MKN-45, LoVo, and PANC-1) were incubated with CDDP (10 μg/ml). The percentage of cells in sub-G1 fraction was measured by flow cytometry. The changes in expression levels of three genes (bax, bcl-2, and survivin) during CDDP treatment were evaluated by real-time reverse transcriptase-polymerase chain reaction (RT-PCR). The percentage of cells in sub-G1 fraction increased after a shorter incubation with CDDP in LoVo cells and also increased between 12 and 24 h CDDP treatment in MKN-45 cells. On the other hand, even with a 24 h incubation with CDDP, the percentage of cells in sub-G1 fraction did not change in PANC-1 cells. The expression level of bax mRNA significantly increased after 24 h treatment with CDDP in MKN-45 cells and it significantly increased after 12 h treatment with CDDP in LoVo cells. Also, in LoVo cells, the expression level of bcl-2 mRNA decreased after 24 h treatment with CDDP. On the other hand, during CDDP treatment, the expression levels of bcl-2 and survivin mRNA significantly increased in PANC-1 cells. These findings indicate that during chemotherapy, changes in expression levels of bax, bcl-2, and survivin may provide information about chemo-sensitivity or the chemo-resistance of tumors.

Related Articles

Journal Cover

September 2002
Volume 9 Issue 5

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Ikeguchi, M., Nakamura, S., & Kaibara, N. (2002). Quantitative analysis of expression levels of bax, bcl-2, and survivin in cancer cells during cisplatin treatment. Oncology Reports, 9, 1121-1126. https://doi.org/10.3892/or.9.5.1121
MLA
Ikeguchi, M., Nakamura, S., Kaibara, N."Quantitative analysis of expression levels of bax, bcl-2, and survivin in cancer cells during cisplatin treatment". Oncology Reports 9.5 (2002): 1121-1126.
Chicago
Ikeguchi, M., Nakamura, S., Kaibara, N."Quantitative analysis of expression levels of bax, bcl-2, and survivin in cancer cells during cisplatin treatment". Oncology Reports 9, no. 5 (2002): 1121-1126. https://doi.org/10.3892/or.9.5.1121